Furthest along
7 approved
15 in Phase 3
Drugs
57
in active trials · 85 in all
Trials
111 active
238 since 2021
Drugs57
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
Approved in China | 25 Dec 2026Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 25 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | C-Met Exon 14 Mutation, Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression and 3 more | ||||
| Open drug page | |||||
PD-1 antibody |
Approved in China | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma and 7 more | ||||
| Open drug page | |||||
— |
Approved in EU | 1 Aug 2027Phase 2 trial completes | |||
| Next date | 1 Aug 2027 · Phase 2 trial completes | ||||
| Also tested for | Gastrointestinal Neuroendocrine Pancreatic Tumor, Diagnosed With Acromegaly, Currently in the Active Stage of the Disease | ||||
| Open drug page | |||||
— |
Approved in China | 30 Sep 2027Phase 3 trial completes | |||
| Next date | 30 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Acute Ischemic Stroke | ||||
| Open drug page | |||||
— |
Approved in China | 30 Dec 2027Phase 3 trial completes | |||
| Next date | 30 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Peripheral T Cell Lymphoma | ||||
| Open drug page | |||||
Topoisomerase inhibitor |
Approved in China | — | |||
| Also tested for | Recurrent Metastatic Nasopharyngeal Carcinoma | ||||
| Open drug page | |||||
DPP-IV inhibitor |
Approved in China | — | |||
| How it works | Helps the body keep more of its own GLP-1 | ||||
| Also tested for | Type 2 diabetes | ||||
| Open drug page | |||||
EGFR-targeted antibody-drug conjugate |
Phase 3 | 30 Nov 2026soonPhase 2 trial completes | |||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Advanced Solid Tumors and 8 more | ||||
| Open drug page | |||||
Docetaxel, albumin-bound (chemotherapy) |
JMT-Bio |
Phase 3 | 16 Dec 2026soonPhase 3 trial completes | ||
| Next date | 16 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer, Locally Advanced Unresectable Esophageal Squamous Carcinoma and 8 more | ||||
| Open drug page | |||||
— |
Phase 3 | 16 Jan 2027Phase 1/2 trial completes | |||
| Next date | 16 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor, Adult, Head and Neck Squamous Cell Carcinoma and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | 28 Apr 2027Phase 3 trial completes | |||
| Next date | 28 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Severe Alopecia Areata, Moderate to Severe Plaque Psoriasis | ||||
| Open drug page | |||||
Bempedoic Acidnot checked |
Adenosine triphosphate-citrate lyase inhibitor |
Phase 3 | 30 Jun 2027Phase 3 trial completes | ||
| Next date | 30 Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Primary Hyperlipidemia | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Oct 2027Phase 1/2 trial completes | |||
| Next date | 30 Oct 2027 · Phase 1/2 trial completes | ||||
| Also tested for | HER2-positive Advanced Breast Cancer, HER2-positive Breast Cancer and 4 more | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Oct 2027Phase 1/2 trial completes | |||
| Next date | 30 Oct 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Advanced/Metastatic Solid Tumors and 4 more | ||||
| Open drug page | |||||
Sirolimus for Injection (Albumin-bound)not checked |
— |
Phase 3 | 30 Nov 2027Phase 2 trial completes | ||
| Next date | 30 Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | HR+/HER2- Advanced/Metastatic Breast Cancer, Advanced Breast Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Dec 2027Phase 3 trial completes | |||
| Next date | 31 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Non-familial Hypercholesterolemia and Mixed Hyperlipidemia, Heterozygous Familial Hypercholesterolemia (HeFH) and 1 more | ||||
| Open drug page | |||||
Irinotecan Liposomenot checked |
Topoisomerase I inhibitor |
Phase 3 | Jan 2028Phase 3 trial completes | ||
| How it works | Chemotherapy that blocks topoisomerase I | ||||
| Next date | Jan 2028 · Phase 3 trial completes | ||||
| Also tested for | Pancreatic Cancer, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma and 2 more | ||||
| Open drug page | |||||
SYH9108not checked |
— |
Phase 3 | 28 Dec 2029Phase 3 trial completes | ||
| Next date | 28 Dec 2029 · Phase 3 trial completes | ||||
| Also tested for | Resistant Hypertension | ||||
| Open drug page | |||||
Albumin-bound docetaxelnot checked |
— |
Phase 3 | — | ||
| Also tested for | Advanced Pancreatic Cancer | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Major Depressive Disorder (MDD) | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 28 other drugs
- SEC filings
- None: it does not file with the US SEC
- Registry names
- 7 names in ClinicalTrials.gov CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
CSPC Megalith Biopharmaceutical Co.,Ltd.
CSPC Ouyi Pharmaceutical Co., Ltd.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
CSPC-NBP Pharmaceutical Co., Ltd. - Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev